KEYNOTE-042 rolls back programmed cell death ligand 1 threshold for non-small cell lung cancer pembrolizumab monotherapy without new insight into those deriving benefit

Affiliations

Editorial

Amy Lauren Cummings et al. Transl Lung Cancer Res. 2019 Dec.

. 2019 Dec;8(Suppl 4):S403-S406.

doi: 10.21037/tlcr.2019.07.06.

¹ Department of Medicine, Division of Hematology/Oncology, David Geffen School of Medicine at the University of California, Los Angeles, CA, USA.

No abstract available

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.
Mok TSK, Wu YL, Kudaba I, Kowalski DM, Cho BC, Turna HZ, Castro G Jr, Srimuninnimit V, Laktionov KK, Bondarenko I, Kubota K, Lubiniecki GM, Zhang J, Kush D, Lopes G; KEYNOTE-042 Investigators. Mok TSK, et al. Lancet. 2019 May 4;393(10183):1819-1830. doi: 10.1016/S0140-6736(18)32409-7. Epub 2019 Apr 4. Lancet. 2019. PMID: 30955977 Clinical Trial.

1. Gandhi L, Rodriguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. N Engl J Med 2018;378:2078-92. 10.1056/NEJMoa1801005 - DOI - PubMed
1. Mok TSK, Wu YL, Kudaba I, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet 2019;393:1819-30. 10.1016/S0140-6736(18)32409-7 - DOI - PubMed
1. United States Food and Drug Administration. FDA expands pembrolizumab indication for first-line treatment of NSCLC (TPS≥1%). Available online: https://www.fda.gov/drugs/fda-expands-pembrolizumab-indication-first-lin.... Accessed 25 June 2019.
1. Garon EB, Hellmann MD, Rizvi NA, et al. Five-Year Overall Survival for Patients With Advanced NonSmall-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study. J Clin Oncol 2019;37:2518-27. 10.1200/JCO.19.00934 - DOI - PMC - PubMed
1. Cummings AL, Garon EB. The ascent of immune checkpoint inhibitors: is the understudy ready for a leading role? Cancer Biol Med 2017;14:341-7. 10.20892/j.issn.2095-3941.2017.0090 - DOI - PMC - PubMed